Crinetics Pharmaceuticals, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts
CRNX Stock | USD 53.94 0.02 0.04% |
Slightly above 64% of Crinetics Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Crinetics Pharmaceuticals suggests that many traders are alarmed. Crinetics Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Crinetics Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Crinetics |
Shares of Crinetics Pharmaceuticals, Inc. have earned a consensus rating of Moderate Buy from the eleven ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12-month price objective
Read at thelincolnianonline.com
Crinetics Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
36
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Crinetics Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Crinetics Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Crinetics Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Crinetics Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Crinetics Pharmaceuticals Fundamental Analysis
We analyze Crinetics Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crinetics Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crinetics Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Crinetics Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Crinetics Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Crinetics Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Crinetics Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Crinetics Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Crinetics Pharmaceuticals Related Equities
FATE | Fate Therapeutics | 1.19 |
| ||
KPTI | Karyopharm Therapeutics | 3.23 |
| ||
XFOR | X4 Pharmaceuticals | 4.92 |
| ||
CRBU | Caribou Biosciences | 5.59 |
| ||
HOOK | Hookipa Pharma | 6.40 |
|
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.